Payment overview · 2025
General Payments
$862.54
25 reported records · 10 companies
Healthcare provider profile · identity verified
Carlos Correa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1629065776
Verified facts
What the public records show
CMS Open Payments records show Carlos Correa, MD received $862.54 in general payments during 2025 across 25 reported records.
Amgen Inc. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 352 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.68 | 20.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.91 | 18.9% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $137.31 | 15.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $124.99 | 14.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $99.85 | 11.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.92 | 5.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.85 | 4.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.16 | 3.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.63 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.24 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $846.27 | 24 |
| Education | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $173.68 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $162.91 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $137.31 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $99.85 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.92 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.45 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 187 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
347 | 101 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
352 | 91 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
187 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 521 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 139 |
| Trulicity | Dulaglutide | 352 | 91 |
| Jardiance | Empagliflozin | 347 | 101 |
| Lisinopril | Lisinopril | 332 | 104 |
| Pioglitazone Hcl | Pioglitazone Hcl | 324 | 101 |
| Metformin Hcl | Metformin Hcl | 314 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 259 | 95 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 219 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 60 |
| Ozempic | Semaglutide | 187 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 70 |
| Metformin Hcl Er | Metformin Hcl | 161 | 51 |
| Ezetimibe | Ezetimibe | 151 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 50 |
| Gabapentin | Gabapentin | 135 | 45 |
| Losartan Potassium | Losartan Potassium | 132 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 47 |
| Alendronate Sodium | Alendronate Sodium | 118 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 36 |
| Tramadol Hcl | Tramadol Hcl | 92 | 17 |
| Amoxicillin | Amoxicillin | 88 | 54 |
| Sertraline Hcl | Sertraline Hcl | 82 | 23 |
| Finasteride | Finasteride | 81 | 26 |
| Eliquis | Apixaban | 79 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 77 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 26 |
| Carvedilol | Carvedilol | 72 | 26 |
| Vascepa | Icosapent Ethyl | 72 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 25 |
| Omeprazole | Omeprazole | 65 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 65 | 29 |
| Farxiga | Dapagliflozin Propanediol | 56 | 17 |
| Mupirocin | Mupirocin | 56 | 33 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Mirtazapine | Mirtazapine | 55 | 14 |
| Chlorthalidone | Chlorthalidone | 54 | 27 |
| Montelukast Sodium | Montelukast Sodium | 54 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 18 |
| Trazodone Hcl | Trazodone Hcl | 50 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 20 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 20 |
| Belsomra | Suvorexant | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 16 |
| Prednisone | Prednisone | 44 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 17 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Furosemide | Furosemide | 33 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Embrace Pen Needle | Pen Needle, Diabetic | 30 | 17 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 20 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Famotidine | Famotidine | 29 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 17 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 21 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 17 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $862.54 · 25 records | Amgen Inc. | AREXVY, BREZTRI, Dexcom G6 Transmitter, Korlym, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error